Medicus Pharma (Medicus Pharma) Change In Receivables : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Medicus Pharma Change In Receivables?

Medicus Pharma's change in receivables for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Medicus Pharma's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .

Medicus Pharma's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Medicus Pharma's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Medicus Pharma's Accounts Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Medicus Pharma's liquidation value for the three months ended in Dec. 2023 was $0.63 Mil.

Medicus Pharma Change In Receivables Historical Data

The historical data trend for Medicus Pharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicus Pharma Change In Receivables Chart

Medicus Pharma Annual Data

Trend

Dec21

Dec22

Dec23

Change In Receivables

Medicus Pharma Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial				-	-	-	-	-

Medicus Pharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Medicus Pharma (OTCPK:MDPLF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Medicus Pharma's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Medicus Pharma's accounts receivable are only considered to be worth 75% of book value:

Medicus Pharma's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1.719	-	1.087	+	0.75 * 0	+	0.5 * 0
=	0.63

Medicus Pharma Change In Receivables Related Terms

Thank you for viewing the detailed overview of Medicus Pharma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Medicus Pharma (Medicus Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medicus Pharma Ltd (OTCPK:MDPLF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

MDCX:Canada

Address

100 King Street West, Suite 3400, One First Canadian Place, Toronto, ON, CAN, M5X 1A4

Website

http://www.medicuspharma.com

Medicus Pharma Ltd will carry on the business of pharmaceutical drug development focused initially on SkinJect. The objective of SkinJect is developing and commercializing novel microneedle arrays for the purpose of treating certain skin cancers, initially basal cell carcinoma.

Medicus Pharma (Medicus Pharma) Headlines

From GuruFocus

Medicus Pharma Opens the Market

By PRNewswire • 10-26-2023